BNTX - CureVac claims patent rights for Pfizer/BioNTech COVID-19 vaccine

• German biotech CureVac N.V. ( NASDAQ: CVAC ) announced on Tuesday that the company filed a lawsuit in Germany over the infringement of certain intellectual property rights related to the COVID-19 vaccine developed by its local rival BioNTech ( BNTX ) and U.S. pharma giant Pfizer ( PFE ).
• The case was filed in the German Regional Court in Düsseldorf against BioNTech ( BNTX ) and two of its subsidiaries, CureVac ( CVAC ) said, noting it would fair compensation for the alleged violations.
• While CureVac ( CVAC ) has added ~1%, both BioNTech ( BNTX ) and Pfizer ( PFE ) have lost ~1% in the pre-market so far.
• However, the company said that it would not seek an injunction or resort to a legal action that could disrupt the production and sales of the blockbuster vaccine.
• The IP rights titled EP 1 857 122 B1, DE 20 2015 009 961 U1 relate to the development of mRNA, the compound behind the Pfizer ( PFE )/ BioNTech ( BNTX ) COVID-19 vaccine.

For further details see: